Browsed by
Author: Member Success

Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations

Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations

June 24, 2020 08:00 AM Eastern Daylight Time

ROCKVILLE, Md. & SAN DIEGO–(BUSINESS WIRE)–Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that the companies have entered into a research and licensing option agreement to combine their platform technologies to combat infectious diseases and cancers. ...  Read more

Sirnaomics and Precision NanoSystems Have Formed a Partnership

Sirnaomics and Precision NanoSystems Have Formed a Partnership

Sirnaomics Inc. (Sirnaomics) and Precision NanoSystems Inc. (PNI) jointly announced a partnership on the development and manufacture of Sirnaomics polypeptide nanoparticle-based RNAi therapeutic product. This strategic joint effort includes the execution of a NanoAssemblr® platform license and supply agreement, plus successful production of multiple batches of Sirnaomics drug product candidates, STP705 and STP707, for ongoing IND enabling safety and toxicity studies, as well as several clinical studies. ...  Read more

Kemp Proteins Affirms Commitment to Quality with ISO 9001:2015 Certification

Kemp Proteins Affirms Commitment to Quality with ISO 9001:2015 Certification

23rd June 2020, Frederick, Maryland, — Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services, today announced that the company has received ISO9001:2015 certification for the development and manufacturing of protein-based products and services to the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s commitment to a culture of continuous improvement focused on providing clients with world-class protein development services. ...  Read more

Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B

Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B

GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B. The Company is also filing clinical trial applications in Canada, Spain, Germany and the United Kingdom. Altimmune plans to initiate a multinational trial in Q4 of this year, subject to an ongoing assessment of the impact of COVID-19 on study conduct. ...  Read more

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

June 12, 2020 09:00 AM Eastern Daylight Time

ROCKVILLE, Md.–(BUSINESS WIRE)–Creatv Microtech, a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy (CRT) and consolidated immunotherapy. Clinical data presented at the ASCO 2020 virtual annual meeting shows the ability to predict which NSCLC patients will benefit from anti-PD-L1/PD-1 immunotherapies. “We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer. Read More Here...  Read more

Vision Technologies Celebrates 20th Anniversary and Moves to New Headquarters

Vision Technologies Celebrates 20th Anniversary and Moves to New Headquarters

GLEN BURNIE, MD, May 1, 2020 – Vision Technologies, Inc. (Vision), a leading network integrator with national and global reach, celebrates 20 years of providing IP-converged technologies. The company offers Internet of Things (IoT) solutions for Audio Visual, Security, Wireless, Intelligent Buildings, as well as Network Infrastructures and Professional Services, plus post-implementation support for commercial, federal, state and local clients across all 50 states and on three continents. ...  Read more